Zogenix (ZGNX) Zohydro ER Fails to Win FDA Panel Backing
Zogenix (Nasdaq: ZGNX) Zohydro ER fails to win FDA panel backing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genocea Biosciences (GNCA) Presents New 12 Month Data on GEN-003
- Adamas Pharma (ADMS) Announces Submission of ADS-5102 NDA to U.S. FDA as Dyskinesia Treatment in PD Patients
- Opexa Therapeutics' (OPXA) Phase 2b Abili-T Trial of Tcelnaa in Secondary Progressive MS Misses Primary Endpoint
Create E-mail Alert Related CategoriesCorporate News, FDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!